Background: Root cause analysis is a technique used to assess systems factors related
; and (ix) reticence of patients to follow up with specialists. 12 Five of these nine factors [1] [2] [3] [4] 7 are related to PSA testing. [5] [6] [7] [8] [9] 13 Given declines in utilization of PSA screening 14, 15 following the 2012 United States Preventative Services Task Force (USPSTF) recommendations against screening, these may play a growing role in the development of metastatic cancer. We therefore designed a case series study to assess the root cause of late diagnosed PCa in a series of men.
In contrast to large, population-based studies, case-series analyses can reveal under-appreciated sources of excess disease or mortality because they illuminate contextual conditions and detailed processes related to adverse events. 16 This technique has been used to analyze serious adverse events such as wrong-site surgeries. 17 The term "sentinel" originally referred a soldier or guard whose job is to stand and keep watch-in modern health care, "sentinel event" is typically used to refer to serious and avoidable adverse events which can alert providers to unsafe health systems. Sentinel event analysis is used to understand the root cause of such events. The number of cases does not have to be large to provide potentially practice changing insights; most case series use 10 or fewer cases. 18 Our hypothesis is that men present with metastatic PCa due, in part, to modifiable health care system-factors rather than disease factors such as aggressive disease.
We conducted a "sentinel event" case series analysis seeking to identify systems issues or barriers to early detection, risk stratification, and effective treatment of clinically significant PCa. At routine clinic visits, the primary treating oncologist asked eligible patients if they would be willing to be interviewed. Before the interview, researchers explained the study and obtained written consent. Two patients declined; one consented patient dropped out when a close family member passed away, leaving 12 white and 3 AA participants.
| MATERIALS AND METHODS

| Setting and recruitment
| Data collection
Interviews of 30 to 60 min were conducted during outpatient clinic visits between January 2014 and December 2015.
Data were gathered from medical records (age, race ethnicity, Gleason score, and PSA at diagnosis) and from a JHU-refined questionnaire and included:
1. Medical history, including PSA testing, and other screening.
2.
Prostate and other health complaints.
3. Perceived quality of care.
4. Health insurance. observed because all the patients who had insurance received primary care in our series ( Table 2 ).
5.
The remaining five groups of factors can be seen in Figure 1 to have played important roles leading to late presentation of PCa in these 15 patients. Four groups of factors were included in our logic model: lack of access to the health system caused by lack of insurance (2 patients), no PSA testing (6 patients), comorbidities (4 patients), and reticence to follow up (1 patient). Aggressive disease was added as the 10th factor because of two patients, one with metastatic disease despite consistently low PSA levels and one with extremely rapidly rising PSA levels. physician (PCP) care, 54% (7/13) of those had routine PSA testing, 57% 
| Lack of routine PSA testing among men with regular primary care
Of the 13 patients with regular PCP care, 46% (6/13) did not have routine PSA testing. Three were 67 or older, one was 41, and two were 59. Both of the men who were older than 74 had continued routine PSA testing. Five patients reported their PCPs said they followed guidelines to avoid routine testing of asymptomatic or older men. One of those PCPs reportedly referred to the guidelines to explain why he wasn't testing PSA in a 59 year old man with a family history of PCa. In the 6th case, the PCPs reasoning was unknown. A year later he presented with a PSA over 1000 ng/mL, a positive bone and CT scan, and a biopsy confirming mPCa. The third patient's PSA rose from 2.1 to 9.2 ng/mL in 12 months; CT confirmed metastatic disease.
| No follow up of actionable PSA
One AA patient whose PSA rose from 28 to 132 ng/mL in 1 year, had a family history of PCa, but ignored his PCP's recommendation to see a urologist. A physician-friend who was a member of his church told him he was already in his 70s, and there was no reason to do a biopsy because PCa "would take 20 years to grow." The friend also told him God said he should "anoint his prostate with oil." While it is possible that he already had metastatic cancer when PSA was 28, workup could potentially have identified treatable localized or locally advanced PCa at that time.
| Comorbidities
Three patients had actionable PSA levels but comorbidities caused them and their physicians to prioritize other medical issues. One patient's physician did not follow up rising PSA levels assuming the patient's lung cancer would lead to death before PCa. However, the lung cancer was slow growing and PCa came to the forefront for treatment decisions. A second patient had localized colon cancer that required significant diagnostic evaluation and treatment. In some cases prioritizing other malignancies is reasonable, however for these two men it led to late stage PCa diagnoses. A third patient had orthopedic comorbidities and thought he had been cured of prostate problems through treatment of benign prostatic hypertrophy. 
| Race and ethnicity
| DISCUSSION
This case series analyzes the root cause of late presentation among a series of men who presented with an initial diagnosis of metastatic cancer at our urban academic medical center. We found that two principal medical decisions (not to test PSA annually and not to follow up on actionable PSA levels) contributed to late stage presentation in 80% of the cases (12/15). The three exceptions were men with aggressive disease who presented with mPCa despite low PSA levels (1.8 ng/mL) in one case and rapid increase in PSA in the two other cases. Metastatic disease despite a PSA under 2 ng/mL is very uncommon, ranging from 1-4% of cases. 22, 23 Of the eight patients who did not have routine PSA testing, two lacked health insurance while six others saw PCPs who decided to forego regular testing because of a combination of PCP preference and comorbidities. In one case, the PCP decided against PSA testing for an AA patient who had a family history of PCa. This decision is consistent with the USPSTF recommendation, which does not take into account any risk factors; but AUA and EAU guidelines call for testing PSA in men with a family history of PCa or are AA, 24, 25 on PCa morbidity, and mortality and how those impacts vary by subpopulation and risk factors. 28 In a regional study during this time (2010) (2011) (2012) (2013) (2014) (2015) , patients were referred at increasingly higher PSA levels and were referred to urologists less often. 29 Despite substantial outreach efforts in our plan to accrue 10 AA patients, we were able to accrue only 3 AA men to the study. Although 7 AA men were candidates for participation, two were not selected because they were unavailable for interviews, and two others dropped out after selection. Family emergencies, restrictive insurance precluding return visits, and other personal issues explained these dropouts.
Each of the 3 AA cases illustrated factors commonly associated with race disparities. One patient lacked insurance leading to no PSA screening. A second had aggressive disease despite low PSA levels. The third patient faced cultural issues in the form of church members who recommended strongly that he allow God to take care of him rather following physician advice to see a specialist in response to actionable PSA levels. Some evidence does exist that PSA screening may be appropriately increased among African-American men. 30 However, the small number of AA men in our study limits detailed insights into this population. With respect to overall patterns of race based PCa incidence, 20% is actually an over representation. 
